Overview

Apixaban for the Acute Treatment of Venous Thromboembolism in Children

Status:
Recruiting
Trial end date:
2023-04-30
Target enrollment:
Participant gender:
Summary
To assess the safety and descriptive efficacy of apixaban in pediatric subjects requiring anticoagulation for the treatment of a VTE.
Phase:
Phase 4
Details
Lead Sponsor:
Pfizer
Collaborator:
Bristol-Myers Squibb
Treatments:
Apixaban